Development of Novel Influenza Virus Vaccines and Vectors
Identifieur interne : 000F93 ( Istex/Corpus ); précédent : 000F92; suivant : 000F94Development of Novel Influenza Virus Vaccines and Vectors
Auteurs : Peter Palese ; Fidel Zavala ; Thomas Muster ; Ruth S. Nussenzweig ; Adolfo García-SastreSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1997.
Abstract
Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.
Url:
DOI: 10.1086/514175
Links to Exploration step
ISTEX:32537E9770107C132CD8586B7FE69D81D557BD02Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Development of Novel Influenza Virus Vaccines and Vectors</title><author><name sortKey="Palese, Peter" sort="Palese, Peter" uniqKey="Palese P" first="Peter" last="Palese">Peter Palese</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</mods:affiliation></affiliation></author><author><name sortKey="Zavala, Fidel" sort="Zavala, Fidel" uniqKey="Zavala F" first="Fidel" last="Zavala">Fidel Zavala</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Muster, Thomas" sort="Muster, Thomas" uniqKey="Muster T" first="Thomas" last="Muster">Thomas Muster</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Nussenzweig, Ruth S" sort="Nussenzweig, Ruth S" uniqKey="Nussenzweig R" first="Ruth S." last="Nussenzweig">Ruth S. Nussenzweig</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Garcia Sastre, Adolfo" sort="Garcia Sastre, Adolfo" uniqKey="Garcia Sastre A" first="Adolfo" last="García-Sastre">Adolfo García-Sastre</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32537E9770107C132CD8586B7FE69D81D557BD02</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1086/514175</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000F93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development of Novel Influenza Virus Vaccines and Vectors</title><author><name sortKey="Palese, Peter" sort="Palese, Peter" uniqKey="Palese P" first="Peter" last="Palese">Peter Palese</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</mods:affiliation></affiliation></author><author><name sortKey="Zavala, Fidel" sort="Zavala, Fidel" uniqKey="Zavala F" first="Fidel" last="Zavala">Fidel Zavala</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Muster, Thomas" sort="Muster, Thomas" uniqKey="Muster T" first="Thomas" last="Muster">Thomas Muster</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Nussenzweig, Ruth S" sort="Nussenzweig, Ruth S" uniqKey="Nussenzweig R" first="Ruth S." last="Nussenzweig">Ruth S. Nussenzweig</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Garcia Sastre, Adolfo" sort="Garcia Sastre, Adolfo" uniqKey="Garcia Sastre A" first="Adolfo" last="García-Sastre">Adolfo García-Sastre</name><affiliation><mods:affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1997-08">1997</date><biblScope unit="vol">176</biblScope><biblScope unit="issue">Supplemet_1</biblScope><biblScope unit="page" from="S45">S45</biblScope><biblScope unit="page" to="S49">S49</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>recombinant</json:string><json:string>vaccine</json:string><json:string>epitope</json:string><json:string>virus vaccine</json:string><json:string>attenuated</json:string><json:string>immune</json:string><json:string>vaccinia</json:string><json:string>recombinant virus</json:string><json:string>palese</json:string><json:string>mucosal</json:string><json:string>yoelii</json:string><json:string>immune response</json:string><json:string>cell epitope</json:string><json:string>virus</json:string><json:string>transfectant virus</json:string><json:string>vaccinia virus recombinant</json:string><json:string>immunization</json:string><json:string>antigenic drift</json:string><json:string>master strain</json:string><json:string>proc natl acad</json:string><json:string>protective immunity</json:string><json:string>novel virus vaccine</json:string><json:string>neuraminidase gene</json:string><json:string>virus recombinant</json:string><json:string>sinai school</json:string><json:string>mucosal immunity</json:string><json:string>virus vector</json:string><json:string>attenuated virus vaccine</json:string><json:string>annual review</json:string><json:string>human virus</json:string><json:string>pandemic strain</json:string><json:string>interpandemic period</json:string><json:string>genetic manipulation</json:string><json:string>virus genome</json:string><json:string>rational design</json:string><json:string>attenuating mutation</json:string><json:string>such virus</json:string><json:string>human population</json:string><json:string>protective immune response</json:string><json:string>vaccinia virus</json:string><json:string>attenuated virus</json:string><json:string>foreign antigen</json:string><json:string>plasmodium yoelii</json:string><json:string>human virus type</json:string><json:string>spleen cell</json:string><json:string>intestinal secretion</json:string><json:string>attenuated master strain</json:string><json:string>recombinant vaccinia virus</json:string><json:string>raven press</json:string><json:string>reassortant virus</json:string><json:string>alternative approach</json:string></teeft></keywords><author><json:item><name>Peter Palese</name><affiliations><json:string>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</json:string><json:string>Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</json:string></affiliations></json:item><json:item><name>Fidel Zavala</name><affiliations><json:string>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Thomas Muster</name><affiliations><json:string>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Ruth S. Nussenzweig</name><affiliations><json:string>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</json:string></affiliations></json:item><json:item><name>Adolfo García-Sastre</name><affiliations><json:string>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</json:string></affiliations></json:item></author><arkIstex>ark:/67375/HXZ-BX71KJWZ-3</arkIstex><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.</abstract><qualityIndicators><score>5.169</score><pdfWordCount>2582</pdfWordCount><pdfCharCount>16263</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><pdfWordsPerPage>516</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>false</refBibsNative><abstractWordCount>160</abstractWordCount><abstractCharCount>1191</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Development of Novel Influenza Virus Vaccines and Vectors</title><pmid><json:string>9240694</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>176</volume><issue>Supplement-1</issue><pages><first>S45</first><last>S49</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1997</json:string><json:string>06-30-97</json:string><json:string>76S</json:string><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>Aviron, Inc</json:string><json:string>New York University</json:string><json:string>University of Chicago</json:string><json:string>Institute for Applied Microbiology, University of Agriculture, Vienna, Austria Approaches</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Fidel Zavala</json:string><json:string>Sinai School</json:string><json:string>Gustave Levy</json:string><json:string>Adolfo Garc</json:string><json:string>Thomas Muster</json:string><json:string>Of</json:string><json:string>Ann Arbor</json:string><json:string>Ruth S. Nussenzweig</json:string><json:string>Herbert Fund</json:string><json:string>Peter Palese</json:string></persName><placeName><json:string>NY</json:string><json:string>Beijing</json:string><json:string>York</json:string><json:string>Wuhan</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[12]</json:string><json:string>[11]</json:string><json:string>[1]</json:string><json:string>[16]</json:string><json:string>[3]</json:string><json:string>Maassab et al. [4]</json:string><json:string>[5]</json:string><json:string>[15]</json:string><json:string>Palese et al.</json:string><json:string>[14]</json:string><json:string>[2]</json:string><json:string>[13]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-BX71KJWZ-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - microbiology</json:string><json:string>2 - infectious diseases</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - microbiology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1997</publicationDate><copyrightDate>1997</copyrightDate><doi><json:string>10.1086/514175</json:string></doi><id>32537E9770107C132CD8586B7FE69D81D557BD02</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Development of Novel Influenza Virus Vaccines and Vectors</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>The University of Chicago Press</publisher><availability><licence>© 1997 by The University of Chicago</licence></availability><date type="Copyright" when="1997">1997</date><date when="1997-08">1997</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Development of Novel Influenza Virus Vaccines and Vectors</title><author xml:id="author-0000" role="corresp"><persName><surname>Palese</surname><forename type="first">Peter</forename></persName><affiliation><orgName type="department">Department of Microbiology</orgName><orgName type="department">Mount Sinai School of Medicine</orgName><orgName type="department">and Department of Medical and Molecular Parasitology</orgName><orgName type="institution">New York University School of Medicine</orgName><orgName type="institution">Institute for Applied Microbiology</orgName><orgName type="institution">University of Agriculture</orgName><address><addrLine>New York, New York</addrLine><addrLine>Vienna, Austria</addrLine></address></affiliation><affiliation role="corresp">Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</affiliation></author><author xml:id="author-0001"><persName><surname>Zavala</surname><forename type="first">Fidel</forename></persName><affiliation><orgName type="department">Department of Microbiology</orgName><orgName type="department">Mount Sinai School of Medicine</orgName><orgName type="department">and Department of Medical and Molecular Parasitology</orgName><orgName type="institution">New York University School of Medicine</orgName><orgName type="institution">Institute for Applied Microbiology</orgName><orgName type="institution">University of Agriculture</orgName><address><addrLine>New York, New York</addrLine><addrLine>Vienna, Austria</addrLine></address></affiliation></author><author xml:id="author-0002"><persName><surname>Muster</surname><forename type="first">Thomas</forename></persName><affiliation><orgName type="department">Department of Microbiology</orgName><orgName type="department">Mount Sinai School of Medicine</orgName><orgName type="department">and Department of Medical and Molecular Parasitology</orgName><orgName type="institution">New York University School of Medicine</orgName><orgName type="institution">Institute for Applied Microbiology</orgName><orgName type="institution">University of Agriculture</orgName><address><addrLine>New York, New York</addrLine><addrLine>Vienna, Austria</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><surname>Nussenzweig</surname><forename type="first">Ruth S.</forename></persName><affiliation><orgName type="department">Department of Microbiology</orgName><orgName type="department">Mount Sinai School of Medicine</orgName><orgName type="department">and Department of Medical and Molecular Parasitology</orgName><orgName type="institution">New York University School of Medicine</orgName><orgName type="institution">Institute for Applied Microbiology</orgName><orgName type="institution">University of Agriculture</orgName><address><addrLine>New York, New York</addrLine><addrLine>Vienna, Austria</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><surname>García-Sastre</surname><forename type="first">Adolfo</forename></persName><affiliation><orgName type="department">Department of Microbiology</orgName><orgName type="department">Mount Sinai School of Medicine</orgName><orgName type="department">and Department of Medical and Molecular Parasitology</orgName><orgName type="institution">New York University School of Medicine</orgName><orgName type="institution">Institute for Applied Microbiology</orgName><orgName type="institution">University of Agriculture</orgName><address><addrLine>New York, New York</addrLine><addrLine>Vienna, Austria</addrLine></address></affiliation></author><idno type="istex">32537E9770107C132CD8586B7FE69D81D557BD02</idno><idno type="ark">ark:/67375/HXZ-BX71KJWZ-3</idno><idno type="DOI">10.1086/514175</idno></analytic><monogr><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="hwp">jinfdis</idno><idno type="publisher-id">jid</idno><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1997-08">1997</date><biblScope unit="vol">176</biblScope><biblScope unit="issue">Supplemet_1</biblScope><biblScope unit="page" from="S45">S45</biblScope><biblScope unit="page" to="S49">S49</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of <hi rend="italic">Plasmodium yoelii</hi> resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Articles</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2019-12-11">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher>
<publisher-name>The University of Chicago Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1086/514175</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Development of Novel Influenza Virus Vaccines and Vectors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Palese</surname><given-names>Peter</given-names></name><xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zavala</surname><given-names>Fidel</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Muster</surname><given-names>Thomas</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Nussenzweig</surname><given-names>Ruth S.</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>García-Sastre</surname><given-names>Adolfo</given-names></name>
</contrib>
<aff><institution>Department of Microbiology, Mount Sinai School of Medicine, and
Department of Medical and Molecular Parasitology, New York
University School of Medicine</institution>, <addr-line>New York, New York</addr-line>; <institution>Institute for Applied Microbiology, University of Agriculture</institution>, <addr-line>Vienna, Austria</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>1997</year>
</pub-date>
<volume>176</volume>
<issue>Supplement_1</issue>
<fpage>S45</fpage>
<lpage>S49</lpage>
<copyright-statement>© 1997 by The University of Chicago</copyright-statement>
<copyright-year>1997</copyright-year>
<abstract>
<p>Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of <italic>Plasmodium yoelii</italic> resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.</p>
</abstract>
</article-meta>
</front>
</article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Development of Novel Influenza Virus Vaccines and Vectors</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Development of Novel Influenza Virus Vaccines and Vectors</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Peter</namePart><namePart type="family">Palese</namePart><affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</affiliation><affiliation>Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fidel</namePart><namePart type="family">Zavala</namePart><affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Muster</namePart><affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ruth S.</namePart><namePart type="family">Nussenzweig</namePart><affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Adolfo</namePart><namePart type="family">García-Sastre</namePart><affiliation>Department of Microbiology, Mount Sinai School of Medicine, and Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">1997-08</dateIssued><copyrightDate encoding="w3cdtf">1997</copyrightDate></originInfo><abstract>Approaches to improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-adapted and genetically engineered influenza viruses containing specific attenuating mutations. It is hoped that these genetically altered viruses, in which the hemagglutinin and neuraminidase genes from circulating strains have been incorporated by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protective immune response in humans. In addition, genetically engineered influenza viruses may provide a means for expressing foreign antigens. Immunization of mice with recombinant influenza and vaccinia viruses expressing specific antigens of Plasmodium yoelii resulted in a dramatic protective immune response against malaria in this model. Mice immunized with recombinant influenza viruses expressing human immunodeficiency virus (HIV) epitopes generated long-lasting HIV-specific serum antibodies and secretory IgA in the secretory nasal, vaginal, and intestinal mucosa. These results suggest that genetically engineered influenza viruses may be developed for use as live virus vaccines against influenza as well as other diseases.</abstract><note type="author-notes">Reprints or correspondence: Dr. Peter Palese, Dept. of Microbiology, Box 1124, Mt. Sinai School of Medicine, 1 Gustave Levy Pl., New York, NY 10029.</note><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>176</number></detail><detail type="issue"><caption>no.</caption><number>Supplement-1</number></detail><extent unit="pages"><start>S45</start><end>S49</end></extent></part></relatedItem><identifier type="istex">32537E9770107C132CD8586B7FE69D81D557BD02</identifier><identifier type="ark">ark:/67375/HXZ-BX71KJWZ-3</identifier><identifier type="DOI">10.1086/514175</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1997 by The University of Chicago</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.0) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/record.json</uri></json:item></metadata><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-BX71KJWZ-3/annexes.pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:32537E9770107C132CD8586B7FE69D81D557BD02
|texte= Development of Novel Influenza Virus Vaccines and Vectors
}}
| This area was generated with Dilib version V0.6.33. |  |